Well the 10Q made me cross eyed. Lots there. Only
Post# of 5066
The debt is building big now in BMSN, and the A/S is HUGE and only half there (o/s). Financials cast a big shadow but being a clinical stage company and small molecules in pipeline is hard to overshadow.
I wish I could share a good guess about what might happen next for BMSN, but I am stumped. Even an RS is not likely to happen for a long time if at all. The big thing needed here is patience.